All cabotegravir articles
-
NewsIsolated viral load test may generate false positive results for people using long-acting PrEP
A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.
-
NewsLong-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV
Long-acting, injectable antiretroviral therapy (ART) suppressed HIV replication better than oral ART in people who had previously experienced challenges taking daily oral regimens and was found safe in adolescents with HIV viral suppression.
-
NewsLong-acting HIV treatment demonstrates efficacy in people with challenges taking daily medicine as prescribed
Long-acting antiretroviral therapy (ART) with cabotegravir and rilpivirine was superior in suppressing HIV replication compared to daily oral ART in people who had been unable to maintain viral suppression through an oral daily regimen, according to interim data from a randomized trial. Source: NIAID Colorized transmission electron micrograph ...
